EXAS logoEXAS
Exact Sciences Corp.

11,220
Loading...
Loading...
News
all
press releases
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·13d ago
News Placeholder
Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·16d ago
News Placeholder
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Zacks·16d ago
News Placeholder
Should You Continue to Hold EXAS Stock in Your Portfolio?
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Zacks·18d ago
News Placeholder
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Zacks·24d ago
News Placeholder
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Zacks·1mo ago
News Placeholder
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Zacks·2mo ago
News Placeholder
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Zacks·2mo ago
News Placeholder
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·2mo ago

Latest EXAS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.